What is the treatment for tinea?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Tinea Infections

For most tinea infections, topical antifungal therapy with azoles (clotrimazole or miconazole) applied twice daily for 2-4 weeks is first-line treatment, except for tinea capitis which always requires oral therapy. 1

Treatment Algorithm by Site of Infection

Tinea Corporis (Body) and Tinea Cruris (Groin)

Topical therapy (first-line):

  • Clotrimazole cream twice daily for 2-4 weeks 1
  • Miconazole cream twice daily for 2-4 weeks 1
  • Treatment should continue for at least one week after clinical clearing 2

Oral therapy (when topical fails or extensive disease):

  • Terbinafine 250 mg daily for 1-2 weeks is particularly effective against Trichophyton tonsurans 1
  • Itraconazole 100 mg daily for 15 days achieves 87% mycological cure rate, superior to griseofulvin's 57% 1
  • Fluconazole 50-100 mg daily for 2-3 weeks or 150 mg once weekly for 2-3 weeks 3

Tinea Pedis (Feet) and Tinea Manuum (Hands)

Topical therapy (first-line):

  • Azole or allylamine antifungals applied once or twice daily for 4 weeks 2, 4
  • Allylamines require only 1-2 weeks of treatment 2

Oral therapy (for hyperkeratotic or extensive disease):

  • Terbinafine 250 mg daily for 2 weeks 3
  • Itraconazole 100 mg daily for 2 weeks or 400 mg daily for 1 week 3
  • Fluconazole 150 mg once weekly (pulse dosing) 3
  • Combination topical plus oral therapy is effective for hyperkeratotic tinea pedis unresponsive to topical monotherapy alone 5

Tinea Capitis (Scalp)

Oral therapy is mandatory; topical therapy alone is inadequate: 6

  • Griseofulvin 20 mg/kg daily for 6-8 weeks is first-line 6
  • For resistant cases, increase griseofulvin to 25 mg/kg daily for prolonged periods 6
  • Terbinafine is more effective for Trichophyton species 6
  • Griseofulvin is more effective for Microsporum species (88.5% vs 67.9% response rate) 6
  • Topical therapy should not be used as it enhances inflammation 5

Tinea Versicolor (Pityriasis Versicolor)

Topical therapy (first-line):

  • Topical antifungal agents reduce spore transmission and are effective 7

Oral therapy (for extensive or resistant disease):

  • Itraconazole 50-100 mg daily for 2-4 weeks 7
  • Fluconazole 400 mg as a single dose or 200 mg daily for 5-7 days 3
  • Note: Terbinafine is ineffective for tinea versicolor 3

Tinea Unguium (Onychomycosis)

Oral therapy is primary treatment:

  • Griseofulvin for fingernails: at least 4 months; toenails: at least 6 months 8
  • Itraconazole and terbinafine are standard treatments 4
  • Topical amorolfine and ciclopirox are approved for milder cases 4

Critical Treatment Principles

Diagnostic confirmation before treatment:

  • Accurate diagnosis through potassium hydroxide preparation microscopy or culture is essential 1, 6
  • Specimens should be collected via scalpel scraping, hair pluck, brush, or swab as appropriate 1
  • Treatment may be started immediately in high-risk populations or when clinical features strongly suggest tinea 6

Monitoring and follow-up:

  • Mycological cure, not just clinical response, is the definitive endpoint 1
  • Follow-up should include both clinical and mycological assessment until clearance is documented 7, 1, 6
  • Repeat mycology sampling is recommended until mycological clearance 1

Baseline testing for oral therapy:

  • Liver function tests are recommended before initiating terbinafine or itraconazole, especially with pre-existing hepatic abnormalities 1

Special Considerations and Drug Interactions

Itraconazole interactions:

  • Enhanced toxicity with warfarin, certain antihistamines, antipsychotics, midazolam, digoxin, and simvastatin 1
  • Licensed for children over 12 years in the UK, used off-label in younger children in some countries 1

Griseofulvin is not first-line for tinea corporis:

  • Requires longer treatment duration, is less effective than terbinafine, and has lower cure rates 1

Fluconazole limitations:

  • Not licensed for tinea in children under 10 years in the UK 1
  • Less cost-effective than terbinafine with limited comparative efficacy data 1

Prevention of Recurrence

Essential preventive measures:

  • Clean contaminated combs and brushes with disinfectant or 2% sodium hypochlorite solution 7, 1, 6
  • Screen and treat all family members, especially with anthropophilic species like Trichophyton tonsurans (over 50% of family members may be affected) 1, 6
  • Avoid skin-to-skin contact with infected individuals 1, 6
  • Do not share towels and personal items 1
  • Cover lesions during treatment 1
  • Proper foot hygiene education is important for tinea pedis 4

Common Pitfalls to Avoid

Complicated presentations requiring modified approach:

  • Interdigital tinea pedis with erosion or contact dermatitis: begin with topical corticosteroid plus oral antifungal, then add topical antifungal after complications resolve 5
  • Tinea facialis near eyes, ears, or mouth: oral antifungals are necessary as topical application is difficult 5
  • Widespread tinea corporis or tinea cruris involving complex skin folds: oral therapy is more practical 5
  • Treatment failure may require extending treatment duration 1

References

Guideline

Treatment of Tinea Corporis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Topical treatment of common superficial tinea infections.

American family physician, 2002

Research

Oral therapy of common superficial fungal infections of the skin.

Journal of the American Academy of Dermatology, 1999

Guideline

Treatment of Tinea Lesions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Tinea Versicolor with Antifungal Agents

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.